Non-selective multi-kinase inhibitors such as cabozantinib and vandetanib are approved for the treatment of MTC, with inhibition extending beyond RET to other kinases such as vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF). This evidence concerns the gene RET and medullary thyroid gland carcinoma.